CorMedix

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CorMedix progresses on DefenCath NDA resubmission amidst financial challenges

CorMedix is actively working towards resubmitting the DefenCath NDA and preparing for commercialization, despite facing challenges in FDA interactions and financial performance. The company's strong cash position provides operational flexibility and readiness for potential NDA approval, with opportunities for growth in addressing CRBSIs.

CorMedix plans DefenCath launch in 2024, strengthens IP protection

CorMedix is strategically positioning for the potential commercial launch of DefenCath in early 2024, pending FDA approvals.
Despite financial challenges in Q1 2023, the company's strong IP protection and engagement strategies offer growth opportunities.

CorMedix reports key milestones and strong financial position in Q2 2023

CorMedix's Q2 2023 Earnings Call highlighted key achievements, financial updates, and strategic initiatives, showcasing the company's progress and readiness for upcoming milestones.
Despite facing challenges such as a net loss increase and operational complexities, CorMedix's strong financial position, milestones achieved, and strategic focus position it well for future growth and success.
With opportunities to drive commercialization, expand market access, and establish partnerships, CorMedix is poised to capitalize on its strengths and navigate challenges effectively in the evolving healthcare landscape.

CorMedix prepares for DefenCath launch with strong cash position

CorMedix is strategically positioned for the commercial launch of DefenCath, with a strong cash position and ongoing discussions with regulatory bodies for reimbursement. Despite challenges in operating expenses and net loss in Q3 2023, the company's focus on key catalysts in 2024 presents significant growth opportunities.

CorMedix reports Q4 loss, eyes profitability in 2024 amid milestones

CorMedix faces challenges with rising operating expenses impacting profitability but has achieved key milestones and optimized field operations.
Opportunities lie in label expansions, reimbursement approvals, and gradual market penetration strategies.
Maintaining financial discipline while pursuing growth initiatives will be crucial for CorMedix's success.
Overall, CorMedix's strategic focus on commercial launch and potential expansions sets the stage for future growth.

CorMedix progresses with DefenCath launch, eyes profitability by 2024

CorMedix is making strides with DefenCath's commercial launch and engaging key dialysis providers for procurement contracts.
Financially, the company aims for breakeven by end of 2024, supported by a credit facility and ample cash reserves.
Challenges include managing operating expenses and evaluating potential M&A opportunities for strategic growth.
Opportunities lie in outpatient commercialization, label expansion, and demonstrating DefenCath's value through real-world evidence studies.

CorMedix sees strong sales growth with DefenCath launch success

CorMedix's successful DefenCath launch generated $5.2 million in sales, with inpatient sales expected to rise in Q4. The company is focused on securing reimbursement from Medicare Advantage plans and funding clinical initiatives without significant dilution.

CorMedix reports strong Q3 results, eyes FDA approvals for growth

CorMedix's Q3 performance exceeded expectations, showing revenue growth and operational improvements.
While facing challenges in revenue guidance variability and increased expenses, the company is poised for EBITDA positivity in Q4.
Strengths lie in product acceptance, market expansion, and commitment to research, with opportunities in new agreements, studies, and FDA approvals.
Careful financial management and successful regulatory milestones will be key to capitalizing on growth opportunities and maintaining profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CorMedix, Inc. (NASDAQ: CRMD) on behalf of long-term stockholders following a class action complaint that was filed against CorMedix on July 22, 2021 with a Class Period from July 8, 2020 to May 13, 2021. Our investigation concerns whether the board of directors of CorMedix have breached their fiduciary duties to the company. The complaint al

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry

CorMedix Inc. Announces the Appointment of Chief Executive Officer

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) a year ago. In parallel, the Company's third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter (“PAAL”) issued by the FDA concurrently with the CRL.

Cormedix Inc. Announces Resubmission of New Drug Application for DefenCath

CorMedix Inc (NASDAQ: CRMD) has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the FDA.  In parallel, the Company's third-party manufacturer submitted responses to the deficiencies identified at the.

CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Inc. (CRMD) CEO Matt David on Q3 2021 Earnings Call Transcript

BERKELEY HEIGHTS, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021, and will host a corporate update conference call at 4:30pm Eastern Time.

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the acceptance for presentation of three abstracts at industry conferences. These include one abstract presented today at the Association of Managed Care Pharmacy (AMCP) Nexus conference in Denver, Colorado, and two abstracts being presented at the American Society of Nephrology (ASN) conference being held virtually November 4 – 8.

CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI

BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced changes to its executive leadership team. Khoso Baluch is retiring from his role as Chief Executive Officer, effective October 4, 2021, and has also resigned from the Company's Board of Directors. John Armstrong, EVP for Technical Operations, is retiring from CorMedix, effective October 4, 2021. The Board has appointed Matt David, M.D., CorMedix's EVP and Chief Financial Officer, as interim Chief Executive Officer, effective immediately. Dr. David will continue to hold his position of Chief Financial Officer.

CorMedix Inc. Announces Executive Leadership Changes

Activision Blizzard

Yalla Group

NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

LAWSUITS FILED AGAINST CRMD, ATVI and YALA - Jakubowitz Law Pursues Shareholders Claims

SelectQuote

Spectrum Pharma

NEW YORK, NY / ACCESSWIRE / September 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: CRMD SLQT SPPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

New York, New York--(Newsfile Corp. - September 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and May 13, 2021, inclusive (the "Class Period"), of the important September 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased CorMedix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

CRMD Final Deadline Today: Rosen, A Leading Investor Rights Law Firm, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action - CRMD

Iterum Therapeutics Plc

Royal Philips

NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, ITRM and PHG

New York, New York--(Newsfile Corp. - September 17, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CorMedix Inc. ("CorMedix") (NASDAQ: CRMD) between October 16, 2019 and May 13, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 20, 2021 - CRMD

Honest Co

Katapult Holdings

NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CRMD, KPLT and HNST

Waterdrop

Zymergen

NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: CRMD ZY WDH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

New York, New York--(Newsfile Corp. - September 17, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a Lead Plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) from July 8, 2020 through May 13, 2021 (the "Class Period"). The lawsuit filed in the...

CRMD INVESTOR LAWSUIT FILING DEADLINE SEPTEMBER 20, 2021: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CorMedix Inc.

NEW YORK, Sept. 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and May 13, 2021, inclusive (the "Class Period"), of the important September 20, 2021 lead plaintiff deadline.

CRMD FINAL DEADLINE MONDAY: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action - CRMD

LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CRMD--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)-- #CRMDstock--The suit alleges defendants issued false statements concerning CorMedix business and prospects, resulting in its stock trading at inflated prices.

EXPANDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Announces that CorMedix Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CRMD

New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that the Company violated federal securities laws.Class Period: October 16, 2019 and May 13, 2021Lead Plaintiff Deadline: September 20, 2021No obligation or cost to you.Learn more about your recoverable losses in CRMD:https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19597&from=5

CRMD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 20, 2021 in the Class Action Filed on Behalf of CorMedix Inc. Limited Shareholders

LOS ANGELES, Sept. 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  September 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) securities between October 16, 2019 and May 13, 2021 , inclusive (the "Class Period").

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CorMedix Inc. (CRMD)

Los Angeles, California--(Newsfile Corp. - September 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. ("CorMedix" or "the Company") (NASDAQ: CRMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 8, 2020 and May 13, 2021, inclusive (the...

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers.

Pomerantz Law Firm Announces the Filing of a Class Action Against CorMedix, Inc., and Certain Officers - CRMD

Annovis Bio

NEW YORK, NY / ACCESSWIRE / September 14, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

News for CorMedix Stock (CRMD)